Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin
Progression‐free survival · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin probably leads to lower progression‐free survival (PFS) compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).
1 finding from 1 review
- Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes onlyHR 0.89 [0.81, 0.98]4 studies · 3699 participantsModerate